Brief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
30/09/2026 23:34
BRIEF-Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock Immix Biopharma, Inc. IMMX.O:
IMMIX BIOPHARMA ANNOUNCES CLOSING OF $125 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK
Source text: ID:nGNX1jk3Rn
Further company coverage: IMMX.O
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary